You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 2, 2024

Claims for Patent: 9,950,042


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,950,042
Title:Extended length botulinum toxin formulation for human or mammalian use
Abstract: An extended duration pharmaceutical composition including a botulinum neurotoxin, an adhesive agent, and a stabilizing macromolecule is disclosed. The composition effectively has all the properties to cause chemodenervation through a facial muscle, or other muscle, that predecessor botulinum toxin preparations have had as well as agents which create a fibrotic adhesion on the under surface of facial muscles (or other muscles) to the facial bone (or other bones) so that the facial bone tethers the under surface of the facial muscle, thereby causing fibrosis to the underlying fat pad. The composition can be used to treat various disorders. Methods of modifying facial contour for functional or cosmetic purposes in a human patient are disclosed which involve injecting a therapeutically effective amount of the disclosed compositions. A method of quantifying the extended duration of the compositions is also disclosed.
Inventor(s): Borodic; Gary E. (Quincy, MA)
Assignee: REVANCE THERAPEUTICS, INC. (Newark, CA)
Application Number:14/754,268
Patent Claims:1. A pharmaceutical composition comprising: (a) a botulinum toxin; and (b) an adhesive agent; wherein the adhesive agent comprises a fibrinogen and an antifibrinolysin.

2. The pharmaceutical composition of claim 1, wherein the adhesive agent further comprises sequentially or simultaneously applied albumin and glutaraldehyde.

3. The pharmaceutical composition of claim 1, wherein the adhesive agent further comprises one or more cyanoacrylate compounds.

4. The pharmaceutical composition of claim 1, wherein the adhesive agent further comprises collagen, a lipolytic agent or a bile acid.

5. The pharmaceutical composition of claim 4, wherein the lipolytic agent comprises phosphatidylcholine or one or more deoxycholines.

6. The pharmaceutical composition of claim 1, further comprising a stabilizing macromolecule selected from the group consisting of a stabilizing protein or a stabilizing sugar.

7. The pharmaceutical composition of claim 6, wherein said stabilizing macromolecule comprises both the stabilizing protein and the stabilizing sugar.

8. The pharmaceutical composition of claim 7, wherein the stabilizing sugar is selected from the group consisting of one or more of lactose, mannitol, trehalose and sucrose.

9. The pharmaceutical composition of claim 6, wherein said stabilizing macromolecule comprises the stabilizing protein selected from the group consisting of one or more of fibrinogen, thrombin, and human serum albumin.

10. The pharmaceutical composition of claim 9, wherein the stabilizing protein is fibrinogen.

11. The pharmaceutical composition of claim 10, wherein the fibrinogen is recombinant fibrinogen.

12. The pharmaceutical composition of claim 9, wherein the stabilizing protein is thrombin.

13. The pharmaceutical composition of claim 12, wherein the thrombin is recombinant thrombin.

14. The pharmaceutical composition of claim 6, wherein the stabilizing macromolecule or adhesive agent is freeze or flash dried.

15. The pharmaceutical composition of claim 6, wherein the botulinum toxin, the adhesive agent, and the stabilizing macromolecule are in a liquid phase.

16. The pharmaceutical composition of claim 6, wherein the adhesive agent further comprises a microparticle to cause adhesion of an undersurface of a muscle to bone.

17. The pharmaceutical composition of claim 6, wherein the botulinum toxin is one or more immune subtypes selected from the group consisting of immune subtypes A1, A2, or A3.

Details for Patent 9,950,042

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Omrix Biopharmaceuticals Ltd EVITHROM thrombin, topical (human) Solution 125247 08/27/2007 ⤷  Try a Trial 2028-12-04
Omrix Biopharmaceuticals Ltd EVITHROM thrombin, topical (human) For Injection 125247 09/17/2009 ⤷  Try a Trial 2028-12-04
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.